Your browser doesn't support javascript.
loading
Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK.
Earl, H M; Hiller, L; Dunn, J; Macpherson, I; Rea, D; Hughes-Davies, L; McAdam, K; Hall, P; Mansi, J; Wheatley, D; Abraham, J E; Caldas, C; Gasson, S; O'Riordan, E; Wilcox, M; Miles, D; Cameron, D A; Wardley, A.
Afiliación
  • Earl HM; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, Cambridge, UK. Electronic address: hme22@cam.ac.uk.
  • Hiller L; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Dunn J; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Macpherson I; University of Glasgow, Institute of Cancer Sciences, Glasgow, UK.
  • Rea D; Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Hughes-Davies L; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • McAdam K; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Oncology, Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK.
  • Hall P; Edinburgh University Cancer Research Centre, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK.
  • Mansi J; Department of Medical Oncology, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust and King's College Medical School, London, UK.
  • Wheatley D; Royal Cornwall Hospitals NHS Trust, Truro, UK.
  • Abraham JE; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, Cambridge, UK.
  • Caldas C; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, Cambridge, UK; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK.
  • Gasson S; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • O'Riordan E; Independent Cancer Patients' Voice, London, UK.
  • Wilcox M; Independent Cancer Patients' Voice, London, UK.
  • Miles D; Mount Vernon Cancer Centre, Northwood, UK.
  • Cameron DA; Edinburgh University Cancer Research Centre, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK.
  • Wardley A; The NIHR Manchester Clinical Research Facility at The Christie, Manchester, UK; University of Manchester, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, Manchester, UK.
Clin Oncol (R Coll Radiol) ; 33(1): 15-19, 2021 01.
Article en En | MEDLINE | ID: mdl-32723485
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Clin Oncol (R Coll Radiol) Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Clin Oncol (R Coll Radiol) Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article